249,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Gebundenes Buch

This third edition has been updated to cover all aspects of chiral drugs from the academic, governmental, industrial, and clinical perspectives. New topics include the use of enzymes in the synthesis and resolution of enantiometrically pure compounds in drug discovery, how stereochemistry impacts decisions made in the absorption, distribution, metabolism, excretion, and toxicity (ADMET) stages of drug discovery, and issues faced during the final stages of the drug development process. It also discusses the impact of International Conference on Harmonisation (ICH) on the use of single isomer…mehr

Produktbeschreibung
This third edition has been updated to cover all aspects of chiral drugs from the academic, governmental, industrial, and clinical perspectives. New topics include the use of enzymes in the synthesis and resolution of enantiometrically pure compounds in drug discovery, how stereochemistry impacts decisions made in the absorption, distribution, metabolism, excretion, and toxicity (ADMET) stages of drug discovery, and issues faced during the final stages of the drug development process. It also discusses the impact of International Conference on Harmonisation (ICH) on the use of single isomer drugs, chiral switches, molecular chiral recognition, and legal perspectives.
Autorenporträt
Professor Krzysztof Jó¿wiak is head of laboratory of medicinal chemistry and neuroengineering of Medical University of Lublin, Poland Dr W John Lough is reader in pharmaceutical analysis in the Department of Pharmacy, Health and Well-Being at the University of Sunderland, UK Irving W. Wainer, Ph.D. is senior investigator, in the Bioanalytical Chemistry and Drug Discovery Section, Laboratory for Clinical Investigation, National Institute of Aging/National Institutes of Health